| Name | Title | Contact Details |
|---|---|---|
Chris Hodes |
Regional Sales Director | Profile |
Steve O'Brien |
SVP, Talent Acquisition | Profile |
Hillary Bochniak |
Chief Human Resources Officer | Profile |
Robyn Aycock |
Regional Sales Director-Southeast | Profile |
Stanford Rudnick |
Interim Chief Financial Officer and Chief Strategy Officer | Profile |
Tahiti Trade Super Nutaceuticals is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Today`s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Cytheris is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MNPHARM SBC is a manufacturer of recombinant regenerative proteins using a proprietary method called molecular farming. We supply these proteins to researchers working on therapeutic development. Our plant based expression method only takes 6 to 8 days. We offer faster production and lower cost resulting in rapid therapeutic development.